Three Bridge Wealth Advisors LLC Sells 78 Shares of Becton, Dickinson and Company (NYSE:BDX)

Three Bridge Wealth Advisors LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 5.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,453 shares of the medical instruments supplier’s stock after selling 78 shares during the quarter. Three Bridge Wealth Advisors LLC’s holdings in Becton, Dickinson and Company were worth $330,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares during the period. E. Ohman J or Asset Management AB raised its position in Becton, Dickinson and Company by 13.4% in the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after acquiring an additional 20,859 shares during the period. Arete Wealth Advisors LLC purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $767,000. Busey Bank grew its position in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after acquiring an additional 2,399 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total value of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now directly owns 36,033 shares in the company, valued at $8,215,163.67. This trade represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 10,544 shares of company stock worth $2,370,309 in the last 90 days. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $225.72 on Thursday. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The business has a 50-day moving average price of $232.36 and a 200-day moving average price of $233.94. The firm has a market cap of $65.46 billion, a price-to-earnings ratio of 37.50, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a share buyback plan on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.84%. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BDX shares. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday. Piper Sandler lifted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.